535 related articles for article (PubMed ID: 18803993)
1. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Rees A; Wilkinson A; Durrington P; Chilcott J
Am J Cardiovasc Drugs; 2008; 8(6):419-27. PubMed ID: 19159125
[TBL] [Abstract][Full Text] [Related]
3. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.
Ara R; Tumur I; Pandor A; Duenas A; Williams R; Wilkinson A; Paisley S; Chilcott J
Health Technol Assess; 2008 May; 12(21):iii, xi-xiii, 1-212. PubMed ID: 18485273
[TBL] [Abstract][Full Text] [Related]
4. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study.
Reckless J; Davies G; Tunceli K; Hu XH; Brudi P
Value Health; 2010; 13(6):726-34. PubMed ID: 20561328
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
Cook JR; Yin D; Alemao E; Drummond M
Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
Davies GM; Vyas A; Baxter CA
J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
[TBL] [Abstract][Full Text] [Related]
7. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
8. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway.
Cook JR; Yin D; Alemao E; Davies G; Krobot KJ; Veltri E; Lipka L; Badia X
Pharmacoeconomics; 2004; 22 Suppl 3():49-61. PubMed ID: 15669153
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.
Laires PA; Ejzykowicz F; Hsu TY; Ambegaonkar B; Davies G
J Med Econ; 2015; 18(8):565-72. PubMed ID: 25788039
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
[TBL] [Abstract][Full Text] [Related]
13. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
Sampalis JS; Bissonnette S; Habib R; Boukas S;
Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
[TBL] [Abstract][Full Text] [Related]
14. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.
Morrone D; Weintraub WS; Toth PP; Hanson ME; Lowe RS; Lin J; Shah AK; Tershakovec AM
Atherosclerosis; 2012 Aug; 223(2):251-61. PubMed ID: 22410123
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.
Bissonnette S; Habib R; Sampalis F; Boukas S; Sampalis JS;
Can J Cardiol; 2006 Oct; 22(12):1035-44. PubMed ID: 17036098
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Collins R; Landray MJ; Gray A; Baigent C; Mihaylova B;
Kidney Int; 2019 Jul; 96(1):170-179. PubMed ID: 31005271
[TBL] [Abstract][Full Text] [Related]
17. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
Nherera L; Calvert NW; Demott K; Humphries SE; Neil HA; Minhas R; Thorogood M
Curr Med Res Opin; 2010 Mar; 26(3):529-36. PubMed ID: 20014994
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
Kazi DS; Penko J; Coxson PG; Guzman D; Wei PC; Bibbins-Domingo K
Ann Intern Med; 2019 Feb; 170(4):221-229. PubMed ID: 30597485
[TBL] [Abstract][Full Text] [Related]
20. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]